Related references
Note: Only part of the references are listed.Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis
Nasim A. Khan et al.
ARTHRITIS AND RHEUMATISM (2012)
A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis
Jeremy Chataway et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials
Kenneth F. Schulz et al.
ANNALS OF INTERNAL MEDICINE (2010)
Surrogate endpoints for EDSS worsening in multiple sclerosis A meta-analytic approach
M. P. Sormani et al.
NEUROLOGY (2010)
MENU LABELING: KNOWLEDGE FOR A HEALTHIER AMERICA
Tamara Schulman
HARVARD JOURNAL ON LEGISLATION (2010)
Magnetic Resonance Imaging as a Potential Surrogate for Relapses in Multiple Sclerosis: A Meta-analytic Approach
Maria Pia Sormani et al.
ANNALS OF NEUROLOGY (2009)
Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria
P. O'Connor et al.
MULTIPLE SCLEROSIS (2009)
Industry funding and the reporting quality of large long-term weight loss trials
O. Thomas et al.
INTERNATIONAL JOURNAL OF OBESITY (2008)
Quality of reporting of randomized controlled trials in general endocrinology literature
Lorena P. Rios et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Ethics of placebo-controlled clinical trials in multiple sclerosis - A reassessment
C. H. Polman et al.
NEUROLOGY (2008)
An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia
JH Montgomery et al.
CONTROLLED CLINICAL TRIALS (2004)
The association between funding by commercial interests and study outcome in randomized controlled drug trials
J Yaphe et al.
FAMILY PRACTICE (2001)
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials
D Moher et al.
LANCET (2001)
Subgroup analysis and other (mis)uses of baseline data in clinical trials
SF Assmann et al.
LANCET (2000)
Share Paper
